Previous 10 | Next 10 |
INPEFA granted broad label across full range of left ventricular ejection fraction, including HFpEF and HFrEF, and for patients with or without diabetes INPEFA reduced the risk of total occurrence of cardiovascular death, hospitalization for heart failure, and urgent heart failure v...
2023-05-26 08:34:32 ET Onfolio Holdings ( ONFO ) +62% Completes Development of Generative AI Search Tool. Elevation Oncology ( ELEV ) +58% . Quhuo Limited ( QH ) +37% Sector Exceeded RMB12 Million in Sales During the Labor Day Holiday, Achieving Impre...
2023-05-19 14:38:24 ET Summary Lexicon ought to find out whether its heart failure candidate sotafligozin will be approved on May 27. The drug has been rejected before - in 2019, in patients with Type 1 diabetes, on safety grounds. Astrazeneca's Farxiga and Lilly's Jardiance h...
2023-05-11 06:50:00 ET Thanks to what could be a looming regulatory approval, shares of Lexicon Pharmaceuticals (NASDAQ: LXRX) are soaring, rising by 33% in the last 30 days and 74% over the last 12 months. Wall Street analysts are on average quite bullish, with the average year-ahe...
Sotagliflozin reduced the risk of cardiovascular death and heart failure readmissions in patients hospitalized for worsening heart failure events in SOLOIST-WHF study Sotagliflozin NDA for treatment of heart failure on track for May 27, 2023 PDUFA action date THE WOODLANDS, Te...
2023-05-02 20:27:08 ET Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2023 Results Conference Call May 02, 2023 05:00 PM ET Company Participants Carrie Siragusa - Executive Director, Corporate Strategy and Investor Relations Lonnel Coats - Chief Executive Officer Jeff W...
2023-05-02 16:32:38 ET Lexicon Pharmaceuticals press release ( NASDAQ: LXRX ): Q1 GAAP EPS of -$0.17 beats by $0.01 . Revenue of $0.02M (-50.0% Y/Y) misses by $0.01M . For further details see: Lexicon Pharmaceuticals GAAP EPS of -$0.17 beats by $0.01, rev...
NDA for Sotagliflozin on Track for May 27th, 2023 PDUFA date Conference Call and Webcast at 5:00 pm Eastern Time THE WOODLANDS, Texas, May 02, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months...
2023-04-29 16:00:00 ET With the first trading day in May coming on Monday, many pharmaceutical companies will be hoping their returns fare better than they did in April. The iShares U.S. Pharmaceuticals ETF ( IHE ) returned a paltry 1.6% in April. The ETF's top two holdings are ...
THE WOODLANDS, Texas, April 28, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its first quarter 2023 financial results on Tuesday, May 2, 2023 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m...
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00...
Launch Preparations Actively Underway; Launch Planned for Early 2025 Lexicon Seeks Approval for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease THE WOODLANDS, Texas, July 16, 20...
New analysis of the pivotal Phase 3 SOLOIST-WHF trial provides additional evidence of positive economic impact on hospitals participating in various alternative payment models (APM) Findings consistent with two peer-reviewed studies published in June 2024 THE WOODLANDS, Texa...